- 1 Title: IVUS Improves Outcomes with SUPERA Stents for the Treatment of Superficial Femoral-
- 2 popliteal Artery Disease
- 3 Authors: Prakash Krishnan (Prakash.Krishnan@mountsinai.org)^a, Raman Sharma
- 4 (Raman.Sharma@mountsinai.org)^a, Sriya Avadhani (Sriya.Avadhani@mountsinai.org)^a, Arthur
- 5 Tarricone (<u>Arthur.Tarricone@mountsinai.org</u>)^a, Allen Gee (Allen.gee97@gmail.com)^a, Serdar
- 6 Farhan (Serdar.Farhan@mountsinai.org)^a, Haroon Kamran (Haroon.Kamran@mountsinai.org)^a,
- 7 Annapoorna Kini (Annapoorna.Kini@mountsinai.org)^a, Samin Sharma
- 8 (<u>Samin.Sharma@mountsinai.org</u>)^a

9 Affiliations

- 10 a. Icahn School of Medicine at the Mount Sinai Hospital
- 11 The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R.
- 12 Kravis Cardiovascular Health Center, Department of Medicine/Cardiology, Icahn School of
- 13 Medicine at Mount Sinai, New York, NY

14 Grant Support

15 There was not grant support for this manuscript

16 Correspondence

- 17 Prakash Krishnan MD FACC
- 18 Phone Number: 212-241-6032
- 19 Fax Number: 212-348-7908
- 20 1 Gustave L. Levy Place Box 1030
- 21 New York, NY 10029
- 22 Prakash.Krishnan@mountsinai.org

23 FINANCIAL DISCOLSURES

- 24 All authors have no financial disclosures to make
- 25
- 26
- 27
- 28
- 29

30 Abstract (210 words)

31	Objectives: To determine the effect of intravenous ultrasound (IVUS) when used adjunctively
32	with nitinol interwoven bare metal stents in the management of femoropopliteal lesions.
33	
34	Background: Nitinol interwoven bare metal stents represent an advancement in stent technology;
35	however nominal deployment remains an area of focus. Intravascular Ultrasound (IVUS) has
36	been shown to improve outcomes in both the coronary and peripheral vasculature by providing
37	the operator with greater vessel detail. The use of adjunctive IVUS with Nitinol bare metal
38	stents has not been widely studied.
39	
40	Methods: This study included a cohort of 200 consecutive patients with peripheral artery disease.
41	All patients were treated with ≥1 Supera bare metal stent, and 91 received adjunctive IVUS
42	imaging prior to stent deployment. Deployment conditions of nominal, compressed, and
43	elongated were measured and the primary clinical outcomes included target lesion reintervention,
44	major and minor, below the knee amputation, and mortality.
45	
46	Results: The patients who received IVUS had a significantly greater number of nominally
47	deployed stents (p<0.001). Patients who had IVUS imaging also had significantly lower
48	reintervention rates compared to those who did not receive IVUS imaging (p=0.047).
49	
50	Conclusion: IVUS and angiography decreases clinically driven target lesion reintervention and
51	increases nominal deployment compared to angiography alone in femoropopliteal lesions treated
52	with interwoven bare metal nitinol stents.

53 **Keywords**

- 54 Intravenous Ultrasound, Supera, Stent, Peripheral Artery Disease
- 55

56 **Condensed Abstract (93 words)**

- 57 This retrospective study was done to examine the utility of intravenous ultrasound when used
- 58 adjunctively for visualization in the management of femoropopliteal lesions in peripheral artery
- 59 disease patients. There was total of 200 subjects and all were treated using the Supera nitinol
- 60 self-expanding stent. By the end of the study, the group of subjects treated with intravenous
- ultrasound had significantly fewer reinterventions and had a greater rate of nominally deployed 61
- stents. These findings suggest the beneficial role intravenous ultrasound has compared to 62
- 63 angiography alone in the management of femoropopliteal lesions with Supera stents.
- 64

Abbreviations 65

- 66 PAD = Peripheral Artery Disease
- 67 CD-TLR = Clinically Driven Target Lesion Reintervention
- IVUS = Intravascular Ultrasound 68
- PTA = Percutaneous Transluminal Angioplasty 69
- 70 DCB = Drug Coated Balloon
- 71
- 72
- 73
- 74
- 75

76 Introduction

77 Peripheral Artery Disease (PAD) affects over 200 million people globally with increasing prevalence among the elderly (>80 years) population.(1) Endovascular management of PAD has 78 79 become the mainstay for treatment; however long term patency remains an area of focus. 80 Endovascular intervention success is multifactorial, with outcomes influenced by multiple 81 variables ranging from clinical presentation to appropriate interpretation of angiography.(2,3) 82 Stent malposition due to over or under sizing has been observed to result in increased clinically driven target lesion reintervention (CD-TLR) and decrease in primary patency. Intravascular 83 84 Ultrasound (IVUS) has been shown to improve outcomes in both the coronary and peripheral 85 vasculature by providing the operator with greater vessel detail specifically assessment of plaque buildup, measurement of lumen diameter, and possible assurance of proper stent deployment.(4) 86 87 In the peripheral vasculature, IVUS use has been observed to significantly improve primary and secondary patency, freedom from any reintervention, freedom from any adverse limb event, 88 89 protective against vascular and non-vascular complications, and increase event-free survival 90 compared to angiography alone.(5-7)

91 The interwoven nitinol stent (Supera) represents an advancement in stenting technology 92 and has been shown to improve primary patency compared to bare metal stents, with rates 93 published as high as 90%.(8-11) Logical explanation of this improvement may be attributed to 94 the inherent helical structure of Supera, allowing greater resistance to compressive arterial forces 95 and resilience to stent fractures.(12) However, there has been variation in the success of studies, 96 with patency rates of Supera ranging from 55% -90%.(13,14) One factor that have been speculated attributing to this variation is the mal-deployment of the Supera stents; and with fewer 97 98 nominally deployed stents, there will likely be greater target lesion revascularization.(15) While

99	nominal deployment is always the operator's objective, success of this has only been observed in
100	approximately 50% of treated subjects. The adjunctive use of IVUS with Supera stent technology
101	has not been widely studied and the objective of this analysis is to examine a cohort of
102	femoropopliteal PAD patients treated with Supera and IVUS vs Supera alone to observe
103	differences in both deployment condition as well as clinical outcomes.
104	
105	Methods
106	Between March 2010 to March 2020, 200 consecutive patients were treated for
107	femoropopliteal PAD with Supera stents. All patients were adults (age \geq 18 years), had a
108	confirmed clinical diagnosis of PAD, and were treated with at least one (≥ 1) Supera stent. All
109	patients were treated by guideline directed medical therapy. This study was approved by the
110	Institutional Review Board of the Icahn School of Medicine at the Mount Sinai Hospital:
111	Program of Protection of Human Subjects Committee.
112	The utility of adjunctive procedures and the duration of dual antiplatelet therapy was
113	under the discretion of the treating physician. Standard institutional practice of clopidogrel
114	(75mg/day), and aspirin (81mg) for 3 months were followed for post-procedure therapy.
115	Deployment conditions were assessed based on angiogram review and conditions were classified
116	as nominal, compressed, and elongated by two physicians independently. All disagreements were
117	resolved by the corresponding author
118	All angiograms were anonymized prior to review by the data collection team. Reference
119	vessel diameter was established through angiography or IVUS analysis when available. The
120	estimation of compression and elongation was determined by the operator, by dividing the
121	nominal stent length according to package insertion directions. Actual deployment length was

measured using a preprocedural attached measuring scale. Optical evaluation of the complete stent was then conducted to examine for signs of elongation or compression. In keeping with the findings in the SUPERB trial⁷, the authors defined the final three Supera stent dimensions as elongation (\geq 10% of package insert length), compression (\leq 10% of package insert length), and nominal (-10% \leq Length \leq +10% of package insert length). 10% was chosen due to the increase in CD-TLR observed in the SUPERB trial⁷ when the Supera deployment was either compressed or elongated greater than 10%.

129 IVUS was performed using a system (Philips Healthcare) for all subsequent cases. 130 Images were acquired with a Volcano Eagle Eye(0.014-inch guidewire) or PV018 (0.018in guide 131 wire) solid-state phased array IVUS catheters. All the treating operators were experienced in the 132 use and interpretation of IVUS and IVUS was performed after pre-dilation and prior to stent deployment. In cases with chronic total occlusion, pretreatment IVUS imaging was performed 133 134 after crossing of the occlusion. Manual pull back performed at a steady rate under fluoroscopic 135 imaging with bookmarking of frames at regular distances in relation to the radiopaque ruler for 136 all cases. In addition for all cases, the frame rate was set to maximum and gain and field of view were optimized. Pullback acquisitions and saved still images were archived on softlink 137 138 international and saved for later analysis. IVUS diameter measurements were obtained at the 139 time of the procedure using the control module measurement software. IVUS diameters of the 140 proximal and distal Reference Vessel Diameter (RVD) were obtained at the most normal 141 appearing section immediately adjacent to the lesion. The IVUS diameter was measured in 142 millimeters and obtained following institutional guidelines by measuring the distance between the intima-lumen boundaries in orthogonal planes and calculating the mean measurement. The 143 144 larger of the two measurements was used as the IVUS RVD. IVUS lesion length (mm) was

145 estimated by identifying the proximal and distal edge of the lesion according to IVUS while 146 under direct fluoroscopic control, and the distance between these points was measured using the 147 angiographic imaging length measurement technique described previously. Additional 148 information including the presence of post-angioplasty dissection was also obtained. 149 Associations were determined between Supera and the IVUS and non-IVUS groups, with 150 examination of the clinical outcome variables: re-intervention, mortality, and amputation. T-tests 151 or Chi-squares were used to compare continuous and categorical variables, respectively through 152 the utility of IBM SPSS Statistical viewer. Associations were presented as Odds Ratios (O.R), 153 Confidence Interval (C.I), p-value. A p≤0.05 was considered significant. All continuous 154 variables were presented as mean \pm standard deviation. Logistic regression models were also 155 conducted in SPSS, using the clinical outcomes: re-intervention, mortality, and amputation as 156 dependent variables and covariates as the variables that were considered significant in the 157 univariate analysis.

158

159 Results

160 A total of 236 SUPERA stents were used to treat 200 patients with lower limb 161 claudication or critical limb ischemia. Ninety one of these patients received IVUS imaging, 162 which was conducted in accordance with institution protocol. After angiographic review, all 163 cases were universally agreed upon. 164 limbs were treated with a single Supera stent, while 36 164 limbs were treated with >1 Supera stents. In the case of the 36 limbs treated with >1 Supera stents, total stent length was used in order to determined compressed, nominal, or elongated. 165 166 Baseline and lesion characteristics were similar between both IVUS and non-IVUS treated 167 cohorts. Vessel diameter was observed to be significantly larger in the IVUS subgroup (5.13mm

vs 4.89mm, p<0.001), lesion length (117.47mm vs 90.64mm p<0.001), dissection (52.7% vs
22.0%, p<0.001) and calcification was also observed to be more frequent in the IVUS subgroup
(Table 1 and 2).

171 All vessel preparation devices were utilized at the discretion of the operator and included percutaneous transluminal angioplasty (PTA), drug coated balloons (DCB), atherectomies or 172 173 thrombectomy (Table 3). There were no significant differences in the adjunctive methods 174 between subgroups. There was a significant difference in the Supera stent size used within the 175 IVUS + angiography cohort compared to angiography alone, with more 5.5 mm (36/91 (40%) vs 36/109 (33%) p<0.05) and 6.0mm (33/91(36%) vs 15/109(14%), p<0.05). IVUS utility was 176 177 associated with a lower CD-TLR: O.R = 0.482 [CI: 0.233,0.998] (p=0.047). There was no 178 observed difference in lower extremity amputation between the two cohorts: O.R = 0.891179 [CI:0.298, 2.670] (p=0.837). 180 IVUS was also associated with stent deployment status. Nominal deployment was 181 achieved more frequently in the presence of IVUS utility: O.R = 2.674 [CI: 1.507,4.747], 182 p<0.001), while elongated deployment was observed greater in the non-IVUS treated population (OR = 3.523 [CI: 1.709, 7.267], p < 0.001) (Table 4). There was a greater rate of compressed 183 deployment in the non-IVUS subgroup, however this was not statistically significant. 184 185 The number needed to treat/number needed to harm (NNT/NNH), with the outcome of re-intervention, showed that on average, 8.3 patients would have to be treated with over not 186 187 being treated with IVUS in order to have one additional patient not have an re-vascularization 188 event. 189

190 Discussion

191 Current findings of this study highlight the plausible benefit of adjunctive IVUS use with 192 Supera stent utilization. Significant differences were observed in angiography + IVUS compared 193 to angiography alone cohorts with regard to RVD (5.13mm vs 4.89mm , p<0.5), lesion 194 length(117.47 vs 90.64 , p<0.5), calcification (35 vs 14 , p<0.001), and dissection (48 vs 20 , 195 p<0.001). Across the primary clinical outcomes, the group treated with IVUS-guidance and 196 Supera proceeded to show a significantly lower rate of re-intervention in comparison to the 197 Supera + angiography alone group at 12 months .

198 Across the board, IVUS has been well regarded for improving clinical outcomes within 199 coronary and iliac lesions, and continues to grow prominence in the scope of peripheral 200 intervention. (16-19) The addition of IVUS in peripheral vascular intervention, has been shown 201 to reduce short term and long term major adverse limb events (MALE) and decreased binary 202 restenosis in complete total occlusion (CTO).(20,21) A recent randomized controlled trial 203 comparing angiography + IVUS to angiography alone in femoropopliteal interventions reported 204 decreased binary restenosis when utilizing IVUS + angiography compared to angiography alone 205 at 12 months; and observed a high rate of disagreement in imaging findings including RVD and 206 lesion length, both of which were underestimated with angiography alone.(22) As endovascular 207 therapies evolve the importance of precise imaging becomes heightened. In the case of DCB 208 underestimating the RVD may result in poor apposition of DCB to vessel wall and ultimately 209 suboptimal drug delivery.(22) Mal-deployment of SUPERA has been suggested as plausible 210 explanation for the large variation of in CD-TLR across the literature with elongation carrying 211 the greatest risk of restenosis compared to nominal deployment. (15) The addition of IVUS has 212 been shown to affect medical decision making with regard to sizing of interventional device, 213 while the goal of our study was not to assess change in management as a result of IVUS use, the

214	authors did find significant differences in lesion characteristics including RVD, lesion length,
215	calcification and dissection.(22) In addition to these findings the Supera devices used in IVUS +
216	angiography arm were significantly larger than that of angiography alone arm and resulted in
217	significantly more nominal deployments than angiography alone (52.3% vs 38.5%, p<0.001).
218	While Supera on its own has historically been effective at treating infra-inguinal
219	superficial femoral artery lesions, the fact remains that sizing is a difficult variable to
220	control.(15,23) In our study, the use of IVUS likely attributed to improved vessel prep,
221	deployment, and ultimately more accurate sizing of Supera stent leading to the observed
222	reduction in CD-TLR. Consistent use of IVUS may improve accurate vessel measurements and
223	possibly reduce the error in stent deployment. These factors in combination could improve the
224	long term clinical outcomes of endovascular procedures.
225	Due to the retrospective design of this study, only associations could be determined from
226	the results. Another limitation was that mortality data was collected solely through EPIC records,
227	since social security numbers were often unavailable, preventing cross verification with national
228	death indexes. The present study also consists of a population from a heavily concentrated urban
229	location, making out findings less representative of all populations.
230	
231	Conclusion:
232	IVUS and angiography decreases clinically driven target lesion reintervention and increases
233	nominal deployment compared to angiography alone in femoropopliteal lesions treated with
234	interwoven bare metal nitinol stents.
235	

236 **Perspectives**

237	IVUS has been known to improve patency, protect from vascular adverse events, and reduce the				
238	need for reintervention. This study explores IVUS as an adjunctive imaging method in the				
239	management of femoropopliteal lesions with the Supera interwoven bare metal nitinol stents.				
240	IVUS with angiography shows improved nominal deployment and reduced CD-TLR when				
241	adjunctively used with Supera stents.				
242					
243	References				
244					
245	1.	Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and			
246	-	evidence-based facts. Atheroscierosis 2018;2/5:3/9-381.			
247	2.	Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent			
248		expansion and neointimal proliferation of oversized Nitinol stents in peripheral			
249		arteries. Cardiovasc Intervent Radiol 2009;32:720-6.			
250	3.	Richard R S. The Importance of Accurate Femoropopliteal Artery Sizing in			
251		Endovascular Therapy. Endovascular Today 2012.			
252	4.	Fornell D. Understanding Intravascular Ultrasound (IVUS) Systems. Diagnostic			
253		and Interventional Cardiology 2009.			
254	5.	lida O, Takahara M, Soga Y et al. Efficacy of intravascular ultrasound in			
255		femoropopliteal stenting for peripheral artery disease with TASC II class A to C			
256		lesions. J Endovasc Ther 2014;21:485-92.			
257	6.	Panaich SS, Arora S, Patel N et al. Intravascular Ultrasound in Lower Extremity			
258		Peripheral Vascular Interventions: Variation in Utilization and Impact on In-			
259		Hospital Outcomes From the Nationwide Inpatient Sample (2006-2011). J			
260		Endovasc Ther 2016;23:65-75.			
261	7.	Krishnan P, Tarricone A, Gee A et al. Analysis of Interwoven Nitinol Stenting for			
262		the Treatment of Critical Limb Ischemia: Outcomes From an Average 3-Year			
263		Follow-up Period. Angiology 2022;73:407-412.			
264	8.	Hiramoto JS, Teraa M, de Borst GJ, Conte MS. Interventions for lower extremity			
265		peripheral artery disease. Nat Rev Cardiol 2018;15:332-350.			
266	9.	Meng FC, Chen PL, Lee CY, Shih CC, Chen IM. Real-World Comparison of Drug-			
267		Eluting and Bare-Metal Stents in Superficial Femoral Artery Occlusive Disease			
268		with Trans-Atlantic Intersociety Consensus B Lesions: A 2-Year, Single-Institute			
269		Study. Acta Cardiol Sin 2018;34:130-136.			
270	10.	Ruiz CF, San Norberto García E, Domingos LF et al. supera Stent in Popliteal			
271		Artery, 2 Years Follow-up Results. European Journal of Vascular and			
272		Endovascular Surgery 2019;58:e455.			

273	11.	Werner M, Paetzold A, Banning-Eichenseer U et al. Treatment of complex
274		atherosclerotic femoropopliteal artery disease with a self-expanding interwoven
275		nitinol stent: midterm results from the Leipzig SUPERA 500 registry.
276		EuroIntervention 2014;10:861-8.
277	12.	Garcia L, Jaff MR, Metzger C et al. Wire-Interwoven Nitinol Stent Outcome in the
278		Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the
279		SUPERB Trial. Circ Cardiovasc Interv 2015;8.
280	13.	de Boer SW, van den Heuvel DAF, de Vries-Werson DAB et al. Short-term Results
281		of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With
282		Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and
283		Long Superficial Femoral Artery Lesions. J Endovasc Ther 2017;24:783-792.
284	14.	San Norberto EM, Flota CM, Fidalgo-Domingos L, Taylor JH, Vaquero C. Real-
285		World Results of Supera Stent Implantation for Popliteal Artery Atherosclerotic
286		Lesions: 3-Year Outcome. Ann Vasc Surg 2020;62:397-405.
287	15.	Garcia LA, Rosenfield KR, Metzger CD et al. SUPERB final 3-year outcomes using
288		interwoven nitinol biomimetic supera stent. Catheterization and Cardiovascular
289		Interventions 2017;89:1259-1267.
290	16.	Buckley CJ, Arko FR, Lee S et al. Intravascular ultrasound scanning improves long-
291		term patency of iliac lesions treated with balloon angioplasty and primary
292		stenting. J Vasc Surg 2002;35:316-23.
293	17.	Kim BK, Shin DH, Hong MK et al. Clinical Impact of Intravascular Ultrasound-
294		Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus
295		Biolimus-Eluting Stent Implantation: Randomized Study. Circ Cardiovasc Interv
296		2015;8:e002592.
297	18.	Liu XM, Yang ZM, Liu XK et al. Intravascular ultrasound-guided drug-eluting stent
298		implantation for patients with unprotected left main coronary artery lesions: A
299		single-center randomized trial. Anatol J Cardiol 2019;21:83-90.
300	19.	Tan Q, Wang Q, Liu D, Zhang S, Zhang Y, Li Y. Intravascular ultrasound-guided
301		unprotected left main coronary artery stenting in the elderly. Saudi Med J
302		2015;36:549-53.
303	20.	Divakaran S, Parikh SA, Hawkins BM et al. Temporal Trends, Practice Variation,
304		and Associated Outcomes With IVUS Use During Peripheral Arterial Intervention.
305		JACC Cardiovasc Interv 2022;15:2080-2090.
306	21.	Tsujimura T, Iida O, Takahara M et al. Clinical Impact of Intravascular
307		Ultrasound–Guided Fluoropolymer-Based Drug-Eluting Stent Implantation for
308		Femoropopliteal Lesions. JACC: Cardiovascular Interventions 2022;15:1569-1578.
309	22.	Allan RB, Puckridge PJ, Spark JI, Delaney CL. The Impact of Intravascular
310		Ultrasound on Femoropopliteal Artery Endovascular Interventions: A
311		Randomized Controlled Trial. JACC Cardiovasc Interv 2022;15:536-546.
312	23.	Palena LM, Diaz-Sandoval LJ, Sultato E et al. Feasibility and 1-Year outcomes of
313		subintimal revascularization with supera([®]) stenting of long femoropopliteal
314		occlusions in critical limb ischemia: The "Supersub" Study. Catheter Cardiovasc
315		Interv 2017;89:910-920.
316		

317 Tables

- 318 Table 1: Baseline
- 319 Table 2: Clinical Parameters
- 320 Table 3: Adjunctive Therapies
- 321 Table 4: Outcomes

Table 1: Baseline	IVUS (-) n=109	IVUS (+) n=91	р
Age	71.4 ± 10.6	72 ± 9.5	0.726
Gender			
Male	58 (53.2%)	44 (48.4%)	0.948
Female	51 (46.8%)	47 (51.6%)	0.948
Diabetes Mellitus	73(67.0%)	69 (75.8%)	0.170
Statin User	95 (87.1%)	82 (90.1%)	0.515
Smoker	87 (80.0%)	62 (68.1%)	0.059
Coronary Artery Disease	90 (82.6%)	68 (74.7%)	0.175
Critical Limb Ischemia	35 (32.1%)	28 (30.8%)	0.839
Hypertension	102 (93.6%)	89 (97.8%)	0.151
Hyperlipidemia	102 (93.6%)	86 (94.5%)	0.783
Rutherford			
1	0 (0.0%)	0 (0.0%)	N.A
2	3 (2.8%)	3 (3.3%)	0.822
3	71 (65.1%)	49 (53.8%)	0.105
4	34 (31.2%)	31 (34.1)	0.666
5	12 (11.0%)	7 (7.7%)	0.428
6	3 (2.8%)	1 (1.1%)	0.422

IVUS (-) n=109	IVUS (+) n=91	р			
Reference Vessel Diameter					
4.89 ± 0.79	5.13 ± 0.78	< 0.001			
43 (39.4%)	11 (12.1%)	< 0.001			
5 (4.6%)	0 (0.0%)	N.A			
10 (9.2%)	11 (12.1%)	0.528			
36 (33.0%)	36 (39.6%)	0.338			
15 (13.8%)	33 (36.3%)	< 0.001			
98.44 ± 36.44	120.3 ± 25.38	0.042			
8 (7.3%)	10 (11.0%)	0.372			
22 (20.2%)	28 (30.8%)	0.087			
23 (21.1%)	11 (12.1%)	0.095			
11 ((10.1%)	11 (12.1%)	0.653			
20 (18.3%)	19 (20.9%)	0.653			
25 (22.9%)	12 (13.2%)	0.083			
90.64 ± 41.7	117.47 ± 49.3	< 0.001			
1.7 ± 1.0	1.7 ± 1.0	0.303			
12 (11.0%)	13 (14.3%)	0.485			
33 (30.3%)	31 (34.1%)	0.567			
32 (29.4%)	21 (23.1%)	0.316			
29 (26.6%)	26 (28.6%)	0.757			
46 (42.2%)	32 (35.2%)	0.310			
	IVUS (-) n=109 4.89 ± 0.79 43 (39.4%) 5 (4.6%) 10 (9.2%) 36 (33.0%) 15 (13.8%) 98.44 ± 36.44 8 (7.3%) 22 (20.2%) 23 (21.1%) 11 ((10.1%) 20 (18.3%) 25 (22.9%) 90.64 ± 41.7 1.7 ± 1.0 12 (11.0%) 33 (30.3%) 32 (29.4%) 29 (26.6%) 46 (42.2%)	IVUS (-) n=109IVUS (+) n=91 4.89 ± 0.79 5.13 ± 0.78 $43 (39.4\%)$ $11 (12.1\%)$ $5 (4.6\%)$ $0 (0.0\%)$ $10 (9.2\%)$ $11 (12.1\%)$ $36 (33.0\%)$ $36 (39.6\%)$ $15 (13.8\%)$ $33 (36.3\%)$ 98.44 ± 36.44 120.3 ± 25.38 $8 (7.3\%)$ $10 (11.0\%)$ $22 (20.2\%)$ $28 (30.8\%)$ $23 (21.1\%)$ $11 (12.1\%)$ $11 (10.1\%)$ $11 (12.1\%)$ $11 (10.1\%)$ $11 (12.1\%)$ $20 (18.3\%)$ $19 (20.9\%)$ $25 (22.9\%)$ $12 (13.2\%)$ 90.64 ± 41.7 117.47 ± 49.3 1.7 ± 1.0 1.7 ± 1.0 $12 (11.0\%)$ $13 (14.3\%)$ $33 (30.3\%)$ $31 (34.1\%)$ $32 (29.4\%)$ $21 (23.1\%)$ $29 (26.6\%)$ $26 (28.6\%)$ $46 (42.2\%)$ $32 (35.2\%)$			

Calcification	14 (12.8%)	35 (38.5%)	< 0.001
Dissection	20 (22.0%)	48 (52.7%)	< 0.001
Thrombus	5 (4.6%)	10 (11.0%)	0.087
Recoil	4 (3.7%)	1 (1.1%)	0.246
Perforation	2 (1.8%)	0 (0.0%)	0.194

Table 3: Adjunctive Therapies	IVUS (-) n=109	IVUS (+) n=91	р
DCB	48 (44.0%)	38 (41.8%)	0.746
РТА	61 (56.0%)	54 (59.3%)	0.630
Thrombectomy	3 (2.8%)	0 (0.0%)	0.910
Laser Atherectomy	1 (1.1%)	0 (0.0%)	0.951
Directional Atherectomy	86 (78.9%)	75 (82.4%)	0.532

Table 4: Outcomes	IVUS (-) n=109	IVUS (+) n=91	р
Deployment			
Nominal	42 (38.5%)	57 (52.3%)	< 0.001
Compressed	29 (26.6%)	22 (20.2%)	0.694
Elongated	38 (34.9%)	12 (11.0%)	< 0.001
Amputation	8 (7.3%)	6 (6.6%)	0.837
Mortality	8 (7.3%)	4 (4.4%)	0.383
Re-intervention	28 (25.7%)	13 (14.3%)	0.047